Breast Cancer Screening with Targeted DNA Methylation Markers
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current risk prediction models for breast cancer are inadequate in accurately identifying women at increased risk, and there is a need for improved methods to detect breast cancer with high sensitivity and specificity.
Innovation Solution
Utilization of novel DNA methylation markers, particularly 327 differentially methylated regions (DMRs), to distinguish between breast cancer tissues and benign tissues, including specific markers for various breast cancer subtypes, combined with methylation analysis techniques such as bisulfite treatment and sequencing, to identify methylation patterns.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current risk prediction models are used for breast cancer screening, then the screening process is simple and widely applicable, but the accuracy in identifying women at increased risk is insufficient
Solution Approach 1:
The patent changes the parameter being measured from general risk factors to specific DNA methylation patterns at CpG islands. By targeting methylated DNA regions associated with breast cancer, the method achieves higher diagnostic accuracy while maintaining a focused approach that balances complexity and effectiveness
Solution Approach 2:
The patent replaces conventional clinical assessment methods with molecular biology techniques, specifically using DNA methylation analysis. This substitution enables more precise detection of breast cancer risk by measuring epigenetic modifications rather than relying on traditional risk prediction models
2Reliability
If DNA methylation analysis is used to detect breast cancer, then the sensitivity and specificity are improved, but the diagnostic method becomes more complex
Solution Approach 1:
The patent extracts and analyzes only the most relevant methylation markers from the entire genome, focusing on specific CpG islands and differentially methylated regions. This extraction approach maintains high diagnostic accuracy while reducing the complexity compared to comprehensive genome-wide methylation analysis
Solution Approach 2:
The patent segments the diagnostic process into specific measurable components, including identification of hypermethylated and hypomethylated CpG islands, and analysis of differentially methylated regions. This segmentation makes the complex methylation analysis more manageable and interpretable
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method provides high sensitivity and specificity in distinguishing breast cancer tissues from benign tissues, enabling effective breast cancer screening and diagnosis.
Implementation Method 1
A third approach begins with bisulfate treatment of the DNA to convert all unmethylated cytosines to uracil
Data Source
AI summary
Provided herein is technology for breast cancer screening and particularly, but not exclusively, to methods, compositions, and related uses for detecting the presence of breast cancer.